Report: Abbott: Pipeline, Products, Performance, Potential TOC

Latest Results
EXECUTIVE SUMMARY
Introduction
CURRENT FINANCIAL POSITION
Company Performance
Business Segment Performance
Geographic Segment Performance
Company Strategy
R&D Strategy
Mergers, Acquisitions and Divestitures
Key Agreements
Production
Employees
Product Performance Forecasts
Key Products
Pipeline Analysis
Discontinued - R&D
ABT-202
Other Factors Affecting the Bottom Line
Conclusions
THERAPEUTIC AREA FOCUS
R&D PIPELINE
INFLAMMATION
Marketed Products
Humira (D2E7, adalimumab, LU-200134)
R&D Projects
ABT-874 (J695)
Segard
Growth Forecast
ANTI-INFECTIVES
Marketed Products
Biaxin/Klacid/Klaricid/Biclar
Omnicef
Others
R&D Products
ABT-492
Olamufloxacin mesilate
Growth Forecast
NEUROSCIENCE
Marketed Products
Depakote/Epival/Valcote
Others
R&D Products
ABT-894
Growth Forecast
VIROLOGY
Marketed Products
Kaletra
Others
R&D Projects
Growth Forecast
CARDIOVASCULAR
Marketed Products
TriCor
Others
R&D Projects
ABT-335
ABT-578
BSF302146
NO 1886
ProLyse
Simdax
Growth Forecast
ANAESTHETICS
Marketed Product
Sevorane/Ultane
Others
Growth Forecast
METABOLIC
Marketed Products
Synthroid
Others
Growth Forecast
ONCOLOGY
Marketed Products
Lupron Depot/Lucrin
R&D Projects
ABT-510
ABT-751
ABT-737
Growth Forecast
GASTROINTESTINAL
Marketed Products
Prevacid
Others
R&D Projects
AU-224
Growth Forecast
OTHERS
Marketed Products
R&D Projects
Asoprisnil
Febuxostat
APPENDIX 1 - FINANCIAL PERFORMANCE
Full Year Results 2006
APPENDIX 2 - KEY AGREEMENTS
ALZA Corporation
Artus GmbH
Astellas
AstraZeneca
Axcan Pharma Inc
Cambridge Antibody Technology Group plc (CAT)
Caprion Pharmaceuticals Inc
Celera Genomics Group
Cephalon Inc
Chiron Corporation
Critical Therapeutics Inc (CT)
Deltanoid Pharmaceuticals Inc
Dharmacon Research Inc
Eisai
Enanta Pharmaceuticals
Hayashibara Biochemical Laboratories (HBL)
ICOS Corporation
Idun Pharmaceuticals Inc
ILEX Oncology Inc
InterMune Inc
LigoCyte Pharmaceuticals Inc
Medarex Inc.
Medicis Pharmaceutical Corporation
MedImmune
Medtronic Inc
MerLion Pharmaceuticals Pte Ltd.
Myriad Genetics Inc.
NeuroSearch A/S
Norwood Abbey Ltd.
Novartis
Orion Corporation
Oscient Pharmaceuticals
Peptech Ltd
Pfizer
Protein Design Labs Inc (PDL)
SkyePharma PLC
Taisho Pharmaceutical Co Ltd
Takeda
Wakunaga Pharmaceutical Co Ltd.
Wakunaga Pharmaceutical Co Ltd.
Discontinued Agreements
Boehringer Ingelheim
Santarus Inc
APPENDIX 3 - INFRASTRUCTURE.
Research And Development Facilities
Manufacturing Facilities
APPENDIX 4 - KEY PHARMACEUTICAL
SUBSIDIARIES/JOINT VENTURES
Subsidiaries
Joint Ventures
APPENDIX 5 - PRODUCT INDEX
Index of Tables
Principal Operating Results
Sales By Business Area
Total Assets By Business Area
Sales By Origin
Long-Term Assets By Geographical Area
Recent Product Approvals
Major Products, Therapeutic Areas and Sales
Major Launched Products, 2006
Major Launched Products, 2006
Major Launched Products, 2006
Major Launched Products, 2006
Major Launched Products, 2006
Major Launched Products, 2006
Major Launched Products, 2006
Major Launched Products, 2006
Major Launched Products, 2006
Index of Charts
Sales By Business Area, 2006
Operating Income (Loss) By Business Area*
Operating Income By Business Area, 2006
Sales By Origin, 2006
Sales of Major Products (2003A-2012E)
Top Selling Products, 2006
Humira Sales (2001A-2011E)
ABT-874 Sales (2009E-2014E)
Biaxin Sales (2001A-2011E)
Omnicef Sales (2001A-2011E)
Depakote Sales (2001A-2011E)
ABT-894 Sales (2010E-2015E)
Kaletra Sales (2001A-2011E)
TriCor Sales (2001A-2011E)
ABT-335 Sales (2010E-2015E)
ABT-578 Sales (2008E-2013E)
Sevorane/Ultane Sales (2001A-2011E)
Synthroid Sales (2001A-2011E)
Leuprolide Sales (2001A-2011E)
ABT-510 Sales (2010E-2015E)
Lansoprazole Sales (2001A-2011E)
Asoprisnil Sales (2009E-2014E)
Febuxostat Sales (2008E-2013E)
Sales, Costs and Operating Income
Profitability and Research Ratios
R&D Expenditure and Capital Expenditure
Current Assets, Liabilities and Ratio
Assets, Cash and Liquidity
Employees and Productivity

Abbott: Pipeline, Products, Performance, Potential

Table of Contents